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Background: We previously identified two hydrolyzable tannins, chebulagic acid (CHLA) and punicalagin (PUG) that
blocked herpes simplex virus type 1 (HSV-1) entry and spread. These compounds inhibited viral glycoprotein
interactions with cell surface glycosaminoglycans (GAGs). Based on this property, we evaluated their antiviral
efficacy against several different viruses known to employ GAGs for host cell entry.
Results: Extensive analysis of the tannins’ mechanism of action was performed on a panel of viruses during the
attachment and entry steps of infection. Virus-specific binding assays and the analysis of viral spread during
treatment with these compounds were also conducted. CHLA and PUG were effective in abrogating infection by
human cytomegalovirus (HCMV), hepatitis C virus (HCV), dengue virus (DENV), measles virus (MV), and respiratory
syncytial virus (RSV), at μM concentrations and in dose-dependent manners without significant cytotoxicity.
Moreover, the natural compounds inhibited viral attachment, penetration, and spread, to different degrees for each
virus. Specifically, the tannins blocked all these steps of infection for HCMV, HCV, and MV, but had little effect on
the post-fusion spread of DENV and RSV, which could suggest intriguing differences in the roles of GAG-
interactions for these viruses.
Conclusions: CHLA and PUG may be of value as broad-spectrum antivirals for limiting emerging/recurring viruses
known to engage host cell GAGs for entry. Further studies testing the efficacy of these tannins in vivo against
certain viruses are justified.
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Viral infections are responsible for causing a significant num-
ber of human diseases, epidemic outbreaks, morbidity, and
mortality. While vaccine efforts have proven successful for
preventing and eradicating some viral infections, many vi-
ruses cannot be targeted by immunization, including dengue
virus (DENV), human cytomegalovirus (HCMV), hepatitis C
virus (HCV), human immunodeficiency virus (HIV), and re-
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reproduction in any medium, provided the orcontrol include the use of antiviral drugs; however, there are
currently few licensed and efficacious drugs available for
prophylactic and therapeutic antiviral treatments. Global
public health is therefore under constant threat of emerging
and re-emerging viral infections, particularly those that do
not currently have effective vaccines or have the potential to
develop drug-resistant mutations [6]. Furthermore, due to in-
creased global travel, trade, and rapid urbanization, increased
numbers of viral pathogens are being introduced or re-
introduced into areas where they are not normally indige-
nous [7]. This is reflected by the recent emergence of viral
outbreaks caused by severe acute respiratory syndrome
(SARS) virus, influenza virus (H1N1 and H5N1), DENV, West
Nile virus (WNV), and measles virus (MV) [7-9]. In addition,
the potential for outbreaks due to the intentional or accidental. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Structures of chebulagic acid (CHLA) and punicalagin
(PUG). The chemical structures of the two hydrolyzable tannins
under study, chebulagic acid (CHLA) and punicalagin (PUG),
are presented.
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in developing antiviral therapies are required to safeguard the
public against viral pathogens.
Most antiviral therapies target defined steps in the viral
life cycle, or more specifically, a particular viral protein.
Examples include nucleoside analogues that inhibit herpes
simplex virus (HSV) replication [10], protease inhibitors
directed against the HCV NS3 protease [11], and neur-
aminidase inhibitors that block the release of influenza
virus particles from infected cells [12]. However, the use
of these antivirals is inevitably associated with the poten-
tial risk of selecting for drug-resistant viruses, which can
pose a significant problem in the clinical management of
these viral infections [10,12,13]. A combination cocktail of
several inhibitors is often necessary to reduce the risk of
generating drug resistant mutants. This is best exemplified
by Highly Active Antiretroviral Therapy (HAART) for
treating HIV infections [14]. However, experience with
combination therapies is still limited, and the potential of
producing viral escape mutants cannot be ruled out. An
alternative, albeit less specific antiviral therapy is inter-
feron (IFN) which, however, is only effective against a
limited number of viral pathogens [15]. Moreover, because
IFN treatment is prohibitively expensive and burdened
with adverse side-effects, the therapy often results in low
patient compliance [16,17]. These characteristics make
IFN impractical for widespread use in clinical settings. In
view of these shortcomings, there is a clearly a need to de-
velop novel and cost-effective antiviral therapeutics, par-
ticularly those that harbor broad-spectrum bioactivities,
which can be employed to control and limit the spread of
viral infections when immunization and standard therap-
ies are unavailable.
Glycosaminoglycans (GAGs) are negatively charged
linear polysaccharides that are typically sulfated and in-
clude chondroitin sulfate (CS) and heparan sulfate (HS).
They represent a repertoire of complex natural glycans
that are localized within extracellular matrices and on cell
surfaces, and exhibit heterogeneous structures that allow
them to bind to a wide range of protein partners such as
adhesion molecules, chemokines, cytokines, growth fac-
tors, and matrix proteins [18]. Thus, GAGs play important
roles in many biologic processes, which have profound
physiological consequences that include cell signaling, in-
flammation, angiogenesis, and coagulation [18,19]. Many
viruses employ GAGs as primary entry factors that facili-
tate the infection of the host cell. These include DENV,
HCMV, HCV, HIV, HSV, MV, RSV, and others [20-32].
Interactions of viral glycoproteins with GAGs are usually
thought to increase the frequency of initial attachment of
viral particles to the target cell surface. They, in turn,
enable subsequent higher affinity binding with virus-
specific entry receptors that promote virus entry. The im-
portance of GAGs in facilitating viral infections has beendemonstrated by using soluble heparin or GAG-deficient
cell lines to block the entry of several viruses [20-31].
In our previous study, we identified chebulagic acid
(CHLA) and punicalagin (PUG) (Figure 1), two hydro-
lyzable tannins isolated from Terminalia chebula Retz.,
(T. chebula) as inhibitors of HSV type 1 (HSV-1) entry
and spread [33]. We demonstrated that the two
structurally-related compounds mediated their antiviral
activities by targeting HSV-1 viral glycoproteins that
interact with cell surface GAGs. Taking note of the fact
that many viruses employ GAGs to initially bind to the
host cell, and based on evidence that CHLA and PUG
may act as GAG-competitors, we explored the antiviral-
potential of these two tannins against a number of viruses
known to interact with GAGs. Viral models included
DENV, HCMV, HCV, MV, and RSV (Table 1). Many of
the diseases associated with these viruses lack preventative
vaccines and/or drug treatment options [1-4,13,34-36]. In-
deed, both CHLA and PUG efficiently inhibited entry and
spread of these viruses to varying degrees. We suggest that
CHLA and PUG have potential as novel cost-effective and
broad-spectrum antivirals for controlling emerging/re-
curring infections by viruses that engage host cell
surface GAGs.
Methods
Cells, Viruses, and Reagents
Dulbecco’s modified Eagle’s medium (DMEM) and alpha
minimal essential medium (AMEM) were purchased from
GIBCO-Invitrogen (Carlsbad, CA, USA). Fetal bovine
serum (FBS), penicillin G, streptomycin, and amphotericin
B were purchased from Chemicon (Billerica, MA, USA).
Heparin, dimethylsulfoxide (DMSO), and in vitro toxicol-
ogy assay kit (XTT based) were purchased from Sigma
(St. Louis, MO, USA).
Vero (African green monkey kidney cells, ATCC CCL-
81), HEL (human embryonic lung fibroblast, ATCC CCL-
Table 1 Viruses used in this study and their requirement







HCMV Herpesviridae dsDNA + +
HCV Flaviviridae ssRNA (+) + +
DENV-2 Flaviviridae ssRNA (+) + +
MV Paramyxoviridae ssRNA (-) + +
RSV Paramyxoviridae ssRNA (-) + +
VSV Rhabdoviridae ssRNA (-) + ?
ADV-5 Adenoviridae dsDNA - +/-
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cells were obtained from the American Type Culture
Collection (ATCC; Rockville, MD, USA) and cultured in
DMEM supplemented with 10% FBS, 200 U/ml penicillin
G, 200 μg/ml streptomycin, and 0.5 μg/ml amphotericin
B. Huh-7.5 (human hepatocarcinoma Huh-7 cell deriva-
tive; provided by Dr. Charles M. Rice, The Rockefeller
University, New York, NY, USA) and HEp-2 (human epi-
thelial cells derived from a larynx carcinoma; provided by
R. Anderson) cells were cultured in the same medium
condition as just described. CHO-SLAM or Chinese ham-
ster ovary cells expressing human signaling lymphocyte
activation molecule, the receptor for wild-type measles,
were generated as previously reported and cultured in
AMEM supplemented with 10% FBS and 800 μg/ml of
G418 [37,38].
HCMV (AD169 strain; provided by Dr. Karen L.
Mossman, McMaster University, Hamilton, ON, Canada),
wild-type human adenovirus type-5 (ADV-5), and VSV-
GFP (vesicular stomatitis virus with green fluorescent
protein tag) have been described elsewhere and viral titers
and antiviral assays were determined by standard plaque
assay using methanol fixation followed by crystal violet
(Sigma) [33,39,40]. Cell-culture derived HCV particles
were produced by electroporation of Huh-7.5 cells using
the Jc1FLAG2(p7-nsGluc2A) construct (genotype 2a;
kindly provided by Dr. Charles M. Rice), which harbors a
Gaussia luciferase reporter that allows detection of virus
infectivity, as previously described [41]. HCV viral titer
and antiviral assays were determined by immunofluores-
cence staining of TCID50 using anti-NS5A 9E10 antibody
(gift from Dr. Charles M. Rice) and luciferase assays.
DENV-2 (dengue virus type 2; strain 16681) and RSV
(serogroup A, Long strain; ATCC VR-26) were propagated
in Vero and HEp-2 cells, respectively [42,43]. Viral titers
and antiviral assays for DENV-2 and RSV were deter-
mined by immunohistochemical staining plaque assay
using anti-flavivirus group antibody (1:1,000; Millipore,
Billerica, MA, USA), anti-RSV fusion protein antibody(1:5,000; Millipore), and goat anti-mouse IgG (H + L)
alkaline phosphatase (AP) conjugate (Invitrogen; DENV-2,
1:5,000; RSV, 1:10,000), followed by development with
Vector Black AP Substrate Kit (Vector Laboratories;
Burlingame, C, USA) based on previously reported
method [42]. MV-EGFP (recombinant Ichinose-B 323
wild-type measles virus isolate, IC323) expressing en-
hanced green fluorescent protein was originally obtained
from Dr. Roberto Cattaneo (Mayo Clinic, Rochester, MN,
USA) and propagated in marmoset B lymphoblastoid cells
(B95a) [44]; viral titer and antiviral assays were determined
by TCID50 on CHO-SLAM cells. The basal medium
containing 2% FBS with antibiotics was used for all virus
infection experiments. Virus concentrations are expressed
as plaque forming units (PFU) per well or multiplicity of
infection (MOI).
Test compounds
CHLA and PUG (Figure 1) were isolated and purified as
previously described, with their structures confirmed by
high-performance liquid chromatographic method coupled
with UV detection and electrospray ionization mass spec-
trometry (HPLC-UV/ESI-M), and their purities checked by
HPLC with photodiode array detection (HPLC-PDA) [33].
Both compounds were dissolved in DMSO and the final
concentration of DMSO was equal to/or below 1% for the
experiments. Heparin served as control and was dissolved
in sterile double-distilled water. For all assays, unless
otherwise specified, test compound concentrations used
were as follows based on antiviral dose response deter-
mined for each specific virus: HCMV (CHLA = 60 μM,
PUG = 40 μM, Heparin = 30 μg/ml); HCV (CHLA =
50 μM, PUG = 50 μM, Heparin = 1000 μg/ml); DENV-2
(CHLA = 25 μM, PUG = 25 μM, Heparin = 200 μg/ml);
MV (CHLA = 90 μM, PUG = 50 μM, Heparin = 10 μg/ml);
RSV (CHLA = 1 μM, PUG = 2 μM, Heparin = 1 μg/ml).
Cytotoxicity assay
Cells (1 × 104 per well of 96-well plate) were treated
with the test compounds for 3 days. Treatment effects
on cell viability (%) and the 50% cytotoxic concentration
(CC50) values of the test compounds were determined
based on the XTT (2,3-bis[2-methoxy-4-nitro-5-sulfo-
phenyl]-5-phenylamino)-carbonyl]-2H-tetrazolium hy-
droxide) assay as previously reported [33].
Dose–response assay for measuring antiviral activities
The respective cell lines and relative viral dose used, as
well as the incubation periods for test compound treat-
ment and for viral cytopathic effects to take place, are in-
dicated in Table 2 and Figure 2A for each specific virus.
For assessing the antiviral activities of the tannins on
the panel of viruses, HEL (1 × 105 cells/well), Vero (2 × 105
cells/well), HEp-2 (1.5 × 105 cells/well), and A549 (2 – 3 ×
Table 2 Cytotoxicity and antiviral activity of CHLA and
PUG against different virus infectionsa




HCMV HEL CHLA 306.32 ± 7.00 25.50 ± 1.51 12.01
PUG 299.32 ± 9.14 16.76 ± 0.88 17.86
HCV Huh-7.5 CHLA 237.61 ± 4.53 12.16 ± 2.56 19.54
PUG 222.61 ± 3.41 16.72 ± 2.55 13.31
DENV-2 Vero CHLA 159.63 ± 7.46 13.11 ± 0.72 12.18
PUG 151.44 ± 9.31 7.86 ± 0.40 19.27
MV CHO-
SLAM
CHLA 351.83 ± 4.54 34.42 ± 4.35 10.22
PUG 283.76 ± 11.54 25.49 ± 2.94 11.13
RSV HEp-2 CHLA 244.17 ± 17.40 0.38 ± 0.05 642.55
PUG 264.83 ± 23.72 0.54 ± 0.04 490.43
VSV A549 CHLA 316.87 ± 9.01 61.28 ± 5.50 5.17
PUG 318.84 ± 4.99 36.98 ± 4.59 8.62
ADV-5 A549 CHLA 316.87 ± 9.01 198.14 ± 14.07 1.60
PUG 318.84 ± 4.99 196.67 ± 20.05 1.62
a Values shown are means obtained from three independent experiments with
each treatment performed in triplicate.
b Cytotoxic effects were evaluated by XTT assay to determine the
concentration of 50% cellular cytotoxicity (CC50) of the tested compounds.
c Antiviral effects were evaluated by infection analysis to determine the effective
concentration that achieved 50% inhibition (EC50) against the specific virus examined.
d SI, selectivity index. SI = CC50/EC50.
Figure 2 Dose response of CHLA and PUG treatments against
multiple viruses. Host cells for each virus (HEL for HCMV; Huh-7.5
for HCV; Vero for DENV-2, CHO-SLAM for MV; HEp-2 for RSV, and
A549 for VSV and ADV-5) were co-treated with viral inoculum and
increasing concentrations of test compounds for 1 – 3 h before
being washed, incubated, and analyzed for virus infection by plaque
assays, EGFP expression analysis, or luciferase assay as described in
Methods. (A) Schematic of the experiment (shown on the left) with
the virus concentration (PFU/well or MOI), co-treatment time (i), and
the subsequent viral incubation period (ii) indicated for each virus in
the table on the right. (B) Antiviral effect of CHLA against multiple
viruses. (C) Antiviral effect of PUG against multiple viruses. Results
are plotted against values for the DMSO control treatment of virus
infections and the data shown are means ± the standard errors of
the mean (SEM) from three independent experiments. See text
for details.
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treated with the respective viral inoculum (Figure 2A) and
increasing concentration of test compounds for 1 – 2 h.
The inoculum and drug mixtures were removed from the
wells that were subsequently washed with PBS twice and
then overlaid with 2% FBS medium containing either
methylcellulose (Sigma; HCMV: 0.6%; DENV-2: 0.75%;
RSV and VSV: 1%) or SeaPlaque agarose (Lonza, Basel,
Switzerland; ADV-5: 1%). After further incubation for
24 h – 10 days depending on the specific virus, wells
containing ADV-5, HCMV, and VSV infections were ana-
lyzed by standard plaque assays, and wells containing
DENV-2 and RSV infections were analyzed by immuno-
histochemical staining as described above. Viral infection
(%) and the 50% effective concentration (EC50) of test
compounds against different viral infections were calcu-
lated as previously described [33].
For evaluating the antiviral activities of the tannins on
MV-EGFP infection, CHO-SLAM cells (2 × 104 cells/
well) were seeded in 96-well plates and viral inoculum
and increasing concentration of the test compounds
were co-added onto the cell monolayer for 1.5 h. The in-
oculum and drug mixtures were then removed and the
wells were washed with PBS twice before overlay with
AMEM containing 2% FBS. After further incubation for
24 h, the plates were then scanned by the Typhoon 9410variable mode imager (Amersham Biosciences; Baie
d’Urfe, Quebec, Canada) and the EGFP expression was
analyzed by ImageQuant TL software (Amersham Bio-
sciences). Viral inhibition (%) and the EC50 for each
compound based on viral EGFP expression were deter-
mined as previously reported [33].
For analyzing antiviral activities of the tannins on
HCV infection, Huh-7.5 cells (1 × 104 cells/well) were
seeded in 96-well plates and the cell monolayer was co-
challenged with the viral inoculum and increasing
concentration of the test compounds for 3 h. The inocu-
lum and drug mixtures were removed from the wells,
followed by washing with PBS twice and overlaying with
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72 h, the supernatant was collected and then assayed for
luciferase activity using the BioLux™ Gaussia Luciferase
Assay Kit (New England Biolabs; Pickering, ON, Canada)
and a luminometer (Promega; Madison, WI, USA). HCV
infectivity was expressed as log10 of relative light units
(RLU) for determining viral inhibition (%) and the EC50
of the drugs against HCV infection was calculated using
GraphPad Prism 5 software (San Diego, CA, USA).
All values were plotted against the DMSO control
treatment of virus infection.
Viral inactivation assays
Viral inactivation assays were performed as previously
described [33] and the incubation periods and viral dose
used are listed in Figure 3A. Different viruses were
mixed with the test compounds and incubated at 37°C
(Figure 3A, long-term). The drug-virus mixtures were
subsequently diluted (50 – 100 fold) to “sub-therapeutic”
(ineffective) concentrations with low serum medium and
then inoculated on to the respective host cells seeded in
multiwell plates. The dilution to sub-therapeutic concen-
tration prevents effective interaction between the drugsFigure 3 Inactivation of viral infections by CHLA and PUG. Different vi
(incubated for 1.5 – 3 h before titration; light gray bars) or short period (im
fold to sub-therapeutic concentrations and subsequent analysis of infection
(shown on the left) with the final virus concentration (PFU/well or MOI), lon
incubation time (ii) indicated for each virus in the table on the right. Analy
indicated in each additional panel. Results are plotted against the DMSO n
the means ± SEM from three independent experiments. See text for detailsand the host cell surface. For comparison, viruses were
also mixed with test compounds and immediately diluted
(no incubation period) to sub-therapeutic concentration
prior to infection (Figure 3A, short-term). Following incu-
bation for viral absorption, the diluted inocula were re-
moved and the wells were washed with PBS twice before
applying the overlay medium. The plates were further in-
cubated before being subjected to assessment by plaque
assays, EGFP expression analysis, or luciferase assay as
described above.
Viral attachment assays
Analyses of drug effect on viral attachment were per-
formed based on host cell infection (method 1) or virus-
specific cellular enzyme-linked immunosorbent assay
(ELISA; method 2) as previously described [33]. Experi-
ments were all carried out at 4°C which allows for virus
binding but precludes entry which occurs most effi-
ciently at 37°C.
In method 1 (Figure 4A), different cell types were pre-
chilled at 4°C for 1 h and then co-treated with dose of
respective viruses and test compounds at 4°C for the in-
dicated times. The inocula and drugs were removed andruses were treated with the test compounds for a long period
mediately diluted; dark gray bars) at 37°C before diluting it 50 – 100
on the respective host cells. (A) Schematics of the experiment
g-term virus-drug incubation period (i), and the subsequent
ses for (B) HCMV, (C) HCV, (D) DENV-2, (E) MV, and (F) RSV are
egative control treatment for virus infection and the data shown are
.
Figure 4 Evaluation of antiviral activities of CHLA and PUG that affect virus attachment and penetration. (A) Schematics of the
experiments with the virus concentration (PFU/well or MOI) and the time of addition and treatment with tannins (i, ii, iii) for each virus in the
associated tables. In virus attachment analysis by Method 1 (light gray bars), monolayers of different cell types were pre-chilled at 4°C for 1 h, and
then co-treated with the respective viruses and test compounds at 4°C (1.5 – 3 h; i) before washing off the inoculates and test compounds for
subsequent incubation (37°C; ii) and examination of virus infection. In virus penetration analysis (dark gray bars), seeded cell monolayers were
pre-chilled at 4°C for 1 h and then challenged with the respective viruses at 4°C for 1.5 – 3 h (i). Cells were then washed and treated with the
test compounds for an additional incubation period (ii) during which the temperature was shifted to 37°C to facilitate viral penetration. At the
end of the incubation, extracellular viruses were removed by either citrate buffer (pH 3.0) or PBS washes and the cells were further incubated (iii)
for analysis of virus infection. Results for (B) HCMV, (C) HCV, (D) DENV-2, (E) MV, and (F) RSV are indicated in each additional panel. Data are
plotted against the DMSO negative control treatment of virus infection and are presented as means ± SEM from three independent experiments.
See text for details.
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twice before applying the overlay medium. After further
incubation at 37°C, plaque assays, EGFP expression
analysis, or luciferase assay were performed as described
above to assess host cell infection.
In method 2 (Figure 5A), different cell types (2 × 104
cells/well) were seeded in 96-well plates and grown over-
night. The cell monolayers were pre-chilled at 4°C for
1 h and then co-treated with the respective viruses
(HCMV, MOI = 5; HCV, MOI = 0.1; DENV-2, MOI = 5;
MV, MOI = 1; RSV, MOI = 5) and various concentrations
of test compounds at 4°C for an additional 2 h. Follow-
ing the virus binding period, the inocula and drugs were
removed and the cell monolayers were washed with ice-
cold PBS before fixation with pre-chilled 4% paraformal-
dehyde (PFA) in PBS for 1 h on ice. At that point, thewells were blocked with 5% bovine serum albumin
(BSA) at 4°C overnight to prevent any non-specific bind-
ing. Bound viruses on the cellular surfaces were then
detected by ELISA assay whereby wells were incubated
with the following respective mouse monoclonal primary
antibodies (diluted in PBS containing 5% BSA) at 37°C
for 1 h before washing with PBST (0.1% Tween 20 in
PBS) three times: anti-HCMV gB antibody (1:10,000;
Thermo Pierce, Rockford, IL, USA), anti-HCV E2 anti-
body (1:20,000; AUSTRAL Biologicals, San Ramon, CA,
USA), anti-flavivirus group antibody (1:5,000) for
DENV-2, anti-measles hemagglutinin antibody (1:5,000;
Millipore), and anti-RSV fusion protein antibody
(1:15,000). Samples were then subjected to incubation
at 37°C for 1 h with goat anti-mouse IgG conjugated
with horseradish peroxidase (HRP; Invitrogen), diluted
Figure 5 Effects of CHLA and PUG against virus binding analyzed by ELISA. Different cell monolayers were pre-chilled at 4°C for 1 h and
then inoculated with the respective viruses in the presence or absence of various concentrations of test compounds at 4°C for an additional 2 h.
Following the virus binding period, the cell monolayers were washed to remove unadsorbed virus, subsequently fixed with 4% PFA, and then
blocked with 5% BSA. ELISA was performed with virus-specific antibodies and HRP-conjugated IgG, followed by development with a TMB
substrate kit. The absorbance was immediately determined at 450 nm and values are expressed as the fold change of absorbance relative to the
mock infection control (cells + DMSO), which is indicated by the dashed line. (A) Schematic of the experiment with the virus concentration (MOI)
and test compound treatment time (i) indicated for each virus in the associated table. Analyses for (B) HCMV, (C) HCV, (D) DENV-2, (E) MV, and
(F) RSV are indicated in each additional panel. Results shown are means ± SEM from three independent experiments. See text for details.
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(HCV), or 1:30,000 (RSV) in PBS containing 5% BSA.
The wells were afterwards washed with PBST three times
and developed with a TMB (3,3′,5,5′-tetramethylbenzidine)
Two-component Microwell Peroxidase Substrate Kit (KPL,
Gaithersburg, MD) at room temperature for 20 min before
stopping the reaction with 1 M phosphoric acid (H3PO4).
The plates were measured with an ELx800 Microplate
reader (Instrument, Inc.; Winooski, VT, USA) at 450 nm.
Viral penetration assay
The viral penetration assay was performed as previously
reported [33] and the incubation periods and viral dose
used are indicated in Figure 4A. Monolayers of differentcell types were pre-chilled at 4°C for 1 h and then
infected for the indicated times with the respective viruses
at 4°C to allow virus binding but not entry. The inocula
were removed and the wells were washed with ice-cold
PBS twice before treating with the test compounds for the
indicated times at 37°C. This shift to 37°C facilitates viral
penetration and therefore allows assessment of drug ef-
fect on viral internalization. The drugs were afterwards
removed and non-internalized extracellular viruses were
detached by either citrate buffer (50 mM Sodium
Citrate, 4 mM KCl, pH 3.0) or PBS washes. The wells
were then further washed with PBS twice prior to cover-
ing the cell monolayers with overlay medium. After
additional incubation at 37°C, plaque assays, EGFP
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as described above.
Analysis of drug effects post viral entry
For examining drug effects post viral entry, cell mono-
layers were infected with respective viruses at 37°C with
the viral dose and incubation times as specified in
Figure 6A. Following the absorption period, the inocula
were removed and extracellular viruses were detached
by citrate buffer or PBS washes as just described before
treating with the test compounds mixed in the overlay
medium at 37°C for the indicated times. Plaque assay,
EGFP expression assessment, or luciferase assay were
performed as described above for analysis. For HCMV,
the infection was titered by standard plaque assay on
newly seeded HEL cells. Alpha interferon (IFN-α) from
human leukocytes (1,000 U/ml; Sigma) was included as
control for HCV.
Viral cell-to-cell spread assay
Viral cell-to-cell spread assay was performed as previously
described [33,45] with some modifications and the viral
dose and incubation periods are indicated in Figure 7A.
Briefly, different cell types were infected with the respect-
ive viruses and extracellular viruses were removed byFigure 6 Post-infection analysis of antiviral effects due to CHLA and P
37°C to allow viral entry, then washed by citrate buffer or PBS to remove e
absence of the test compounds for infection analysis. (A) Schematic of the
infection time (i), and test compound treatment period post-infection (ii) in
(B) HCMV, (C) HCV, (D) DENV-2, (E) MV, and (F) RSV are indicated in each a
infection. Data shown are means ± SEM from three independent experimecitrate buffer or PBS washes as specified earlier. The wells
were then covered with overlay medium containing either
methylcellulose (DENV-2: 0.75%; RSV: 1%), SeaPlaque
agarose (Lonza; MV: 1%), or in the case of HCMV with
0.1% of neutralizing Gamunex antibodies (purified clinical
human IgGs; provided by Dr. Andrew C. Issekutz,
Dalhousie University, Halifax, NS, Canada) [33]. The over-
lay medium helps limit viral secondary infection, thus
allowing monitoring of cell-to-cell spread of virus in the
presence or absence of the drugs. The plates were incu-
bated until initial plaque formation, to which the test
compounds were then added into the overlay medium
and monitored in subsequent incubation for analysis of
viral plaque size by immunofluorescence assay. The fusion
inhibitory peptide (FIP, Z-D-Phe-L-Phe-Gly-OH, 200 μM;
Sigma) also served as control for MV [46].
The examination of HCV spread is based on previ-
ously described protocol with some modifications [47].
Huh-7.5 cells were electroporated with HCV Jc1FLAG2
(p7-nsGluc2A) RNA (10 μg) as described above to estab-
lish random productive infections in the cell population,
and then mixed with naïve cells at a ratio of 1:1 before
seeding in 12-well plates. Assembled HCV particles
(within 24 – 48 h post-transfection) would transmit to
neighboring cells that do not harbor viral RNA duringUG. Cell monolayers were inoculated with the respective viruses at
xtracellular viruses, and subsequently incubated in the presence or
experiment (left) with the virus concentration (PFU/well or MOI), virus
dicated for each virus in the table shown on the right. Results for
dditional panel. IFN-α treatment was included as control for HCV
nts. See text for details.
Figure 7 Examination of CHLA and PUG treatment on virus cell-to-cell spread. (A) Schematic of the experiment (left) with the virus
concentration (PFU/well) and step-wise incubation periods (i, ii, iii) indicated for each virus in the table on the right. Virus infections were
established (i) in the different cell types by direct inoculation (HCMV, DENV-2, MV, and RSV) or electroporation of viral RNA (HCV; *), and the cell
monolayers were washed with citrate buffer or PBS before being covered with an overlay medium that prevents secondary infection. Initial virus
plaques were allowed to form in the subsequent infections (ii), and then the test compounds were added to the overlay medium for an
additional time of incubation (iii) before analysis of viral plaque size by immune fluorescence microscopy. Five random virus-positive plaques at
the endpoint of the experiment were evaluated for each treatment group of viruses, and the data was plotted as “fold change of plaque area”
against the size of the initial viral plaques formed prior to test compound treatment. Analyses for (B) HCMV, (C) HCV, (D) DENV-2, (E) MV, and (F)
RSV are indicated in each additional panel. The S29 cell line and the FIP inhibitor were included as controls for HCV and MV, respectively. Results
shown are means ± SEM from three independent experiments and representative micrographs of the evaluated plaques are provided in
Additional file 1 Figure S1, Additional file 2 Figure S2, Additional file 3 Figure S3, Additional file 4 Figure S4 and Additional file 5 Figure S5. See
text for details.
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bation period [48]. Medium was changed 24 h post-
electroporation with an overlay medium containing the
test drugs or control and 0.5% methylcellulose, and the
plates were further incubated for 5 days before analysis
of HCV-positive foci through immunostaining. The S29
cell line (provided by Dr. Rodney S. Russell, Memorial
University of Newfoundland, St. John’s, NL, Canada),
which is a Huh-7 derivative deficient in the HCV recep-
tor CD81, does not allow cell-to-cell transmission of
HCV infection and was included as control [49].
For immunofluorescence analysis of viral plaque size
due to spread, the overlay media were removed and the
wells were fixed with ice-cold methanol before blocking
with 3% BSA. Samples were then treated at 37°C for 1 h
with the respective mouse monoclonal primary anti-
bodies diluted in PBS containing 3% BSA: anti-HCMV
gB antibody (1:1,000), anti-NS5A 9E10 antibody forHCV (1:25,000), anti-flavivirus group antibody (1:400)
for DENV-2, and anti-RSV fusion protein antibody
(1:1,000). After incubation, the wells were washed with
PBS three times before applying Alexa Fluor 488 goat
anti-mouse IgG (H + L) antibody (Invitrogen), diluted at
1:1,000 (HCMV and RSV) or 1:400 (DENV-2 and HCV)
in PBS containing 3% BSA. Following incubation at 37°C
for 1 h, the samples were washed with PBS three times
prior to visualization by fluorescence microscopy. The
fluorescence expression of MV-EGFP could be readily
detected without addition of antibodies. Photomicrographs
were taken at × 100 magnification (Leica Microsystems;
Wetzlar, Germany) and viral plaque sizes were then ana-
lyzed with MetaMorph software (Molecular Devices;
Sunnyvale, CA, USA). In the case of HCV, cellular nu-
clei were stained with Hoechst dye (Sigma) prior to
visualization and the number of cells in the virus-
positive foci was determined. For all virus tested, a total
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http://www.biomedcentral.com/1471-2180/13/187of five random virus-positive plaques were evaluated for
each treatment group per independent experiment.
Comparison was made between viral plaques stained
prior to drug addition and those at the endpoint of the
experiment, and the data were plotted as “fold change
of plaque area”.
Results
Broad-spectrum antiviral effects of CHLA and PUG
CHLA and PUG were evaluated for their antiviral effects
against a panel of enveloped viruses whose entry in-
volves cellular surface GAGs (Table 1). Vesicular stoma-
titis virus (VSV) and adenovirus type 5 (ADV-5) were
included for comparison. The 50% indices of cytotoxicity
(CC50) and effective antiviral concentrations (EC50), as
well as the selective index (SI = CC50/EC50), were deter-
mined for each virus infection host cell system and are
listed in Table 2. As shown in Figure 2, CHLA and PUG
displayed broad-spectrum antiviral effects in a dose-
dependent manner. Both compounds exhibited signifi-
cant inhibitory effect on enveloped viruses known to
engage GAGs for infection, including HCMV, HCV,
DENV-2, MV, and RSV, with their EC50 < 35 μM and SI >
10 (Table 2). Both tannins were especially effective against
RSV with their EC50 values being < 1 μM. The two com-
pounds, however, displayed only limited efficacy (SI < 10)
against infections by VSV and ADV-5. This is consistent
with the fact that these viruses have previously been
shown not to require GAGs for entry. VSV can infect
GAG-deficient cells [22,23,50], whereas HS-mediated
entry is only important for ADV-5 in the absence of its
primary receptor CAR (coxsackievirus and adenovirus re-
ceptor) and can only be inhibited to a maximum of 50%
by soluble heparin [51,52]. For the remainder of the stud-
ies, we focused on the effects of the tannins against
HCMV, HCV, DENV-2, MV, and RSV.
Free virus particles are inactivated by CHLA and PUG
CHLA and PUG were previously observed to inactivate
HSV-1 particles and prevent their interaction with the
host cell surface [33]. We examined whether the tannins
could also inactivate the different enveloped viruses and
prevent subsequent infection. These natural products
were pre-incubated with the viruses and then diluted to
sub-therapeutic concentrations prior to infecting the re-
spective host cell. Results indicated that both CHLA and
PUG were able to interact with HCMV, HCV, DENV-2,
MV, and RSV virions. Their effects were irreversible and
abrogated subsequent infections (Figure 3). A 60 – 80%
block against the paramyxoviruses MV and RSV was
observed, whereas near 100% inhibition was achieved
against HCMV, HCV, and DENV-2. The data suggest
that CHLA and PUG can directly inactivate these free
virus particles and neutralize their infectivity.CHLA and PUG inhibit virus entry-related steps
In further characterizing the antiviral mechanism(s) in-
volved, we explored the effect of CHLA and PUG against
HCMV, HCV, DENV-2, MV, and RSV attachment to the
host cell surface and upon subsequent membrane fusion.
The temperature change between 4°C (permitting virus
binding but not entry) and 37°C (facilitating virus entry/
penetration) allows examination of the drug effect on each
specific event [53]. Both tannin compounds effectively
prevented attachment of the investigated viruses as shown
by readouts of inhibition of infection (method 1; Figure 4)
and by ELISA-based binding assays using virus-specific
antibodies to detect bound virus on the cell monolayer
(method 2; Figure 5). The inhibition of virus attachment
by CHLA and PUG were similar against HCMV, HCV,
DENV-2, and RSV, and ranged from 90 – 100% (Figure 4).
Against MV, PUG appeared to be more effective than
CHLA, and inhibition of entry varied between 50 – 80%.
The compounds’ ability to abolish binding of the above vi-
ruses was confirmed by the decrease of virions detected
on cell surfaces. This occurred in a dose-dependent
manner with increasing concentrations of the tannins
(Figure 5).
To see whether the CHLA and PUG retained their ac-
tivity during the virus penetration phase, the test viruses
were allowed to bind to the cell surface at 4°C and then
allowed to penetrate the target cell membrane by a
temperature shift to 37°C in the presence or absence of
the tannins. CHLA and PUG were again observed to im-
pair virus entry by these viruses, resulting in 50 – 90%
protection of the host cell from infection from the virus
being examined (Figure 4). Heparin exhibited similar in-
hibitory effects as the tannins against attachment of the
test viruses, but was less potent in inhibiting cell pene-
tration by HCMV, HCV, and MV (< 40% inhibition on
average). Therefore, CHLA and PUG are able to abro-
gate host cell binding and penetration by HCMV, HCV,
DENV-2, MV, and RSV during the cell entry process.
Control of virus spread post-infection by CHLA and PUG
We next determined the antiviral activity of the two hy-
drolyzable tannins in controlling spread of established
infections. Target cell monolayers were infected with the
respective test virus, and then incubated with or without
the compounds. As shown in Figure 6, both CHLA and
PUG effectively inhibited HCMV, HCV, and MV infec-
tions (80 – 100% protection), but were ineffective against
the growth of DENV-2 and RSV (< 25%). To further valid-
ate the tannins’ effect on virus cell-to-cell transmission,
we examined the effects of the drugs on viral plaque size.
The change in the area of the plaques was measured using
either viral immunofluorescence or EGFP-tagged reporter
viruses. Neutralizing antibodies, methylcellulose or agar-
ose were included in the overlay medium to prevent
Lin et al. BMC Microbiology 2013, 13:187 Page 11 of 15
http://www.biomedcentral.com/1471-2180/13/187secondary infection of uninfected cells throughout the
monolayer, ensuring that viral spread occurs via intercellu-
lar junctions between neighboring infected and virus-free
populations. The data indicated that viral plaques from
HCMV, HCV, and MV infections were restricted by
CHLA and PUG to near initial size, whereas plaques due
to DENV-2 and RSV infections were unaffected and ex-
panded further (Figure 7 and Additional file 1: Figure S1,
Additional file 2: Figure S2, Additional file 3: Figure S3,
Additional file 4: Figure S4 and Additional file 5: Figure
S5). These results are in agreement with the data obtained
following post-entry drug treatment in Figure 6, where
HCMV, HCV, and MV, but not DENV-2 and RSV, were
shown to be sensitive to the tannins’ antiviral effects.
Thus, it appears that the two tannins are effective in limit-
ing post-infection spread of HCMV, HCV, and MV, but
are inefficient in preventing cell-to-cell transmission of
DENV-2 and RSV. Heparin, on the other hand, displayed
limited effect against the spread of the viruses post-entry
(Figures 6 and 7). The window of antiviral activity from
CHLA, PUG, and heparin at different stages of viral entry
and spread are summarized in Table 3.
Discussion
The inhibition of virus-host cell entry is an effective
antiviral control strategy. Based on the way a virus
infects a host cell through interactions between viral
glycoproteins and cellular membrane molecules, coun-




HCMV CHLA +++ ++ +
PUG +++ ++ +
Heparin + ++ +
HCV CHLA +++ +++ +
PUG +++ +++ +
Heparin ++ + +
DENV-2 CHLA +++ +++ +
PUG +++ +++ +
Heparin ++ +++ +
MV CHLA ++ ++ +
PUG ++ +++ +
Heparin ++ +++ +
RSV CHLA +++ +++ +
PUG +++ +++ +
Heparin + +++ +
a Inhibitory effect (%) relative to DMSO control: +++ > 75%; ++ 50–75%; + 25–50%;
b Results from the highest inhibitory concentration of the compounds were used.For example, protective antibodies elicited by vaccines
bind to viral particles and prevent infection [54]. An-
other strategy consists of using monoclonal antibodies
or small molecules to bind host cell receptors and block
virus interactions. Examples include an antibody di-
rected against the HCV receptor claudin 1, and another
is the antagonist maraviroc, which interacts with the
HIV coreceptor CCR5 [14,55]. Another HIV inhibitor
called enfuvirtide blocks gp41-mediated membrane fu-
sion during virus entry. Amantidine blocks influenza
M2 ion channel activity during entry and viral assembly
[14,56]. On the other hand, non-specific approaches
directed against the virus can influence membrane flu-
idity (lipid bilayer intercalator LJ001), membrane fusion
(rigid amphipathic fusion inhibitors, RAFIs) [57,58], or
neutralize surface charge (cationic amphipathic sterol,
squalamine) [59]. These are effective against a wide
range of enveloped viruses. Similarly, we recently con-
sidered GAG receptors as targets for potential antiviral
therapy. Two natural molecules of the hydrolyzable tan-
nin class, CHLA and PUG, possess GAG-competing
properties [33]. In this study, both compounds displayed
significant in vitro antiviral activity against a variety of
viruses, suggesting that blocking interaction with GAGs
is a feasible way to prevent infection by some viruses.
Our finding adds to the list of molecular strategies that
are being developed to prevent and limit viral infections.
We previously showed that CHLA and PUG exerted
their antiviral effects against HSV-1 by binding viralnst different viruses
Window of antiviral effectsa
Penetration Post-infection Cell-to-cell spread
od 2b
++ ++ +++ +++
+ ++ +++ +++
++ + - -
++ +++ +++ +++
++ +++ +++ +++
++ - + -
++ +++ - -
++ +++ - -
++ ++ - -
+ ++ +++ +++
+ +++ +++ +++
+ + - -
++ ++ - -
++ +++ - -
+ ++ - -
- < 25%. Heparin was included for comparison.
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In the current study, these compounds were demon-
strated to be effective against infection by other viruses,
including HCMV, HCV, DENV-2, MV, and RSV, whose
entry is known to be sensitive to neutralization by hep-
arin (Table 3). Similar to HSV-1 [33], the tannins are hy-
pothesized to bind to viral glycoproteins on these viruses
and the cell surfaces of infected cells, blocking virus at-
tachment, entry, and cell to cell spread. The two tannins
may target more than one step of infection, including
attachment, membrane fusion, and cell-to-cell fusion.
Many viral glycoproteins have multiple roles including
binding to host cell surface GAGs, interaction with
higher affinity receptors, and mediating membrane fu-
sion [25,33,60-64]. Since CHLA and PUG could not
block the spread of DENV-2 and RSV, this might reflect
situations where the inhibitors interact with specific sites
on the viral glycoproteins involved with attachment,
membrane fusion, or cell spread, but not all these func-
tions. Conformational changes in the viral glycoproteins
could result from binding to the tannins and interactions
with the cellular microenvironment may vary for the
different viruses. For example, heparin was observed to
be relatively ineffective against post-entry spread for all
viruses examined. This could be due to the fact that the
molecular size of heparin limits its accessibility to viral
glycoproteins in the intercellular junctions [33]. In
addition, the tannins displayed differential efficacies
against the viruses examined (Table 2). It is interesting
that CHLA and PUG appeared to be particularly select-
ive against RSV, which could be due to higher affinity of
the compounds against the RSV glycoproteins. Detailed
structure-activity relationship (SAR) studies coupled with
the analysis of individual viral glycoproteins would be
necessary to clarify these issues. In addition, the use of gen-
etically altered virus lacking certain glycoproteins, for ex-
ample the DeltaG RSV with deleted glycoprotein G [31],
could further help clarify the tannins’ antiviral mechanism.
Although vaccines represent the preferred method for
protection against viruses, they have limited use against
individuals who are already infected with a virus. Vac-
cines are also associated with problems of supply, cost of
development, coverage and deployment, and efficacy
against newly emerging and rapidly mutating viruses [65].
While some antiviral therapies have proven successful,
treatment of many pathogenic viral infections have yet to
be developed or approved. These include several of the
infectious agents investigated in this study. The clinical
value of current antiviral drugs is also frequently com-
promised by development of drug resistant variants
causing recurrence of viral infections. Broad-spectrum an-
tivirals may offer some relief in the treatment of these in-
fections. Although many viruses use GAGs to initiate
infection, therapies exploiting this interaction have yet tobe developed. Heparin, which is also a type of GAG, is
known to block the interaction of viral glycoproteins with
GAGs in cell culture studies. However, it is not clinically
useful in vivo for frequent/long-term administration due
to side effects related to its anticoagulation activity [66].
Conversely, while the CHLA and PUG are structurally dif-
ferent from heparin, they also target the GAG-interacting
properties of viruses and possess a much higher potency.
In vivo toxicological and metabolic studies of these tannins
have been explored with both showing minimal toxicity
[67,68]. Furthermore, the two compounds could be mass-
produced by chemical synthesis or extracted from T.
chebula, which is widespread throughout Southeast Asia,
making them attractive, cost-effective drug candidates
[69-72]. Therefore, development of broad-spectrum anti-
virals using CHLA and PUG or their structure as lead
compounds could be useful. They could help control vi-
ruses such as HCV, DENV, MV, and RSV, especially in
epidemic areas and resource-poor countries where active
vaccine or commercial programs are unavailable. Potential
applications include formulations of the tannins as topical
creams, gels, aerosol inhalers, or incorporating these com-
pounds in materials, such as wipes, surgical masks, and
protective gloves.
Conclusions
In conclusion, we have demonstrated that CHLA and
PUG have the ability to function as broad-spectrum anti-
virals in vitro. They effectively prevented infections by vi-
ruses utilizing GAG-assisted entry, and included HCMV,
HCV, DENV, MV, and RSV. These natural molecules
could serve as new therapeutic agents and help limit infec-
tions by viruses for which vaccines or FDA-licensed drugs
do not yet exist. Future clinical applications and studies
investigating their efficacy in vivo against specific viruses
should be explored.
Additional files
Additional file 1: Figure S1. Examination of CHLA and PUG treatment
on HCMV cell-to-cell spread. HEL cell monolayers were inoculated and
infected with HCMV for 2 h, washed with PBS to remove excess surface
bound virus, and covered with an overlay medium to prevent secondary
infection. Initial virus plaques were allowed to form in the subsequent
infections and CHLA, PUG, Heparin, DMSO control were added to the
overlay medium for an additional incubation time before analysis of viral
plaque size by immune fluorescence microscopy at 5 days post-infection
as described in Methods. Representative virus plaques/foci are shown
after three independent experiments were performed. Scale bar indicates
100 μm.
Additional file 2: Figure S2. Examination of CHLA and PUG treatment
on HCV cell-to-cell spread. Huh-7.5 cells were electroporated with full-
length HCV replicon RNA and covered with an overlay medium to
prevent secondary infection. Initial virus plaques were allowed to form in
the subsequent infections and CHLA, PUG, Heparin, and DMSO control
were added to the overlay medium for an additional incubation time
before analysis of viral plaque size by immune fluorescence microscopy
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http://www.biomedcentral.com/1471-2180/13/187at 7 days post-electroporation as described in Methods. Representative
virus plaques/foci are shown after three independent experiments were
performed. Scale bar indicates 100 μm.
Additional file 3: Figure S3. Examination of CHLA and PUG treatment
on DENV-2 cell-to-cell spread. Vero cells were inoculated and infected
with DENV-2 for 1.5 h, washed with citrate buffer to remove excess
surface bound virus, and covered with an overlay medium to prevent
secondary infection. Initial virus plaques were allowed to form in the
subsequent infections and CHLA, PUG, Heparin, and DMSO control were
added to the overlay medium for an additional incubation time before
analysis of viral plaque size by immune fluorescence microscopy at
6 days post-infection as described in Methods. Representative virus
plaques/foci are shown after three independent experiments were
performed. Scale bar indicates 100 μm.
Additional file 4: Figure S4. Examination of CHLA and PUG treatment
on MV-EGFP cell-to-cell spread. CHO-SLAM cells were inoculated and
infected with MV-EGFP for 1.5 h, washed with citrate buffer to remove
excess surface bound virus, and covered with an overlay medium to
prevent secondary infection. Initial virus plaques were allowed to form in
the subsequent infections and CHLA, PUG, Heparin, FIP, and DMSO
control were added to the overlay medium for an additional incubation
time before analysis of viral plaque size by EGFP fluorescence microscopy
at 48 h post-infection as described in Methods. Representative virus
plaques/foci are shown after three independent experiments were
performed. Scale bar indicates 100 μm.
Additional file 5: Figure S5. Examination of CHLA and PUG treatment
on RSV cell-to-cell spread. HEp-2 cells were inoculated and infected with
RSV for 1.5 h, washed with citrate buffer to remove excess surface bound
virus, and covered with an overlay medium to prevent secondary
infection. Initial virus plaques were allowed to form in the subsequent
infections and CHLA, PUG, Heparin, and DMSO control were added to
the overlay medium for an additional incubation time before analysis of
viral plaque size by immune fluorescence microscopy at 48 h post-
infection as described in Methods. Representative virus plaques/foci are
shown after three independent experiments were performed. Scale bar
indicates 100 μm.
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